PDF(1112 KB)
PDF(1112 KB)
PDF(1112 KB)
拓扑替康对HPB-AM细胞MAGE基因表达的影响
Effect of topotecan on MAGE gene expression of HPB-AM cells
目的：探讨抗肿瘤新药拓扑替康（TPT）对T细胞淋巴瘤系HPB-AM细胞株黑色素病抗原（MAGE）基因表达的影响。方法：以T细胞淋巴瘤系HPB-AM细胞株为研究对象，采用RT-PCR方法检测TPT作用不同时间、不同浓度时对HPB-AM细胞株MAGE基因表达的影响。结果：以0.05 μmol/L， 0.10 μmol/L， 0.15 μmol/L和0.20 μmol/L终浓度的TPT作用于HPB-AM细胞，作用12 h后检测MAGE mRNA，随着TPT浓度的增加，MAGE-3 mRNA和MAGE-4 mRNA的表达水平均明显下调，实验组与空白对照组相对表达量比较，在浓度为0.10，0.15和0.20 μmol/L的TPT作用后差异具有显著性意义(P<0.05)。用浓度0.10 μmol/L的TPT作用于HPB-AM细胞系，作用4，8，12，16 h后检测MAGE mRNA，随着TPT作用时间增长，MAGE-3 mRNA和MAGE-4 mRNA的表达水平明显下调。作用12 h和16 h后，实验组与空白对照组相对表达量比较差异具有显著性意义(P<0.05)。结论：拓扑替康能抑制HPB-AM细胞中MAGE mRNA的表达，且呈剂量和时间依赖性。［中国当代儿科杂志，2009，11（8）：679-682］
OBJECTIVE: To investigate whether topotecan, a novel anti-tumor angent, down-regulates gene expression of melanoma antigen-encoding (MAGE) in HPB-AM cells. METHODS: MAGE mRNA expression of HPB-AM cells was detected by RT-PCR 4, 8, 12 and 16 hrs after different concentrations (0.05, 0.10, 0.15 and 0.20 μmol/L) of topotecan treatment. RESULTS: MAGE mRNA expression of HPB-AM cells decreased with increasing concentrations of topotecan 12 hrs after treatment. The MAGE mRNA expression of HPB-AM cells treated by 0.10, 0.15 and 0.20 μmol/L of topotecan was significantly lower than that in the blank control group (P<0.05). MAGE mRNA expression of HPB-AM cells was significantly reduced in a time-dependent manner after 0.10 μmol/L of topotecan treatment. The MAGE mRNA expression of HPB-AM cells treated by 0.10 μmol/L of topotecan was significantly lower than that in the blank control group 12 and 16 hrs after treatment (P<0.05). CONCLUSIONS: Topotecan is capable of inhibiting the expression of MAGE mRNA of HPB-AM cells in a time- and dose-dependent manner.［Chin J Contemp Pediatr, 2009, 11 (8):679-682］
MAGE / Topotecan / HPB-AM cell
［1］van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma［J］. Science, 1991, 254(5038):1643-1647.
［2］Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLAA1［J］. Int J Cancer, 1999, 80(2):219-230.
［3］De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family［J］. Immunogenetics, 1994, 40(5):360-369.
［4］Muscatelli F, Walker AP, De Plaen E, Stafford AN, Monaco AP. Isolation and characterization of a MAGE gene family in the Xp21.3 region［J］. Proc Natl Acad Sci USA, 1995, 92(11):4987-4991.
［5］Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, et al. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin′s lymphoma: a National Cancer Institute of Canada Clinical Trials Group study［J］. Leuk Lymphoma, 2002, 43(8):1581-1587.
［6］Russo V, Dalerba P, Ricci A, Bonazzi C, Leone BE, Mangioni C, et al. MAGE BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas［J］. Int J Cancer, 1996, 67(3):457-460.
［7］Hara I, Hara S, Miyake H, Yamanaka K, Nagai H, Gohji K, et al. Expression of MAGE genes in testicular germ cell tumors［J］. Urology, 1999, 53(4):843-847.
［8］Pratesi G, Tortoreto M, Corti C, Giardini R, Zunino F. Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts［J］. Br J Cancer, 1995, 71(3):525-528.
［9］De Smet C, Courtois SJ, Faraoni I, Lurquin C, Szikora JP, De Backer O, et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene［J］. Immunogenetics, 1995, 42(4):282-290.
［10］Mou DC, Cai SL, Peng JR, Wang Y, Chen HS, Pang XW,et al. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells［J］. Br J Cancer, 2002, 86(1):110-116.
